drugset / Trial / NCT05105243
Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers
RandomizedSequentialTriple-blindTreatment
Summary
Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.
Timeline
- Start
- 2022-01-17
- Primary completion
- 2022-10-30
- Completion
- 2022-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CVN766 | Small molecule | 5 mg | Oral |
| Comparator | CVN766 | Small molecule | 15 mg | Oral |
| Comparator | CVN766 | Small molecule | 45 mg | Oral |
| Comparator | CVN766 | Small molecule | 125 mg | Oral |
| Comparator | CVN766 | Small molecule | 250 mg | Oral |
Indications
No indication recorded.